title: New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
abstract: BACKGROUND
  Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients.
  
  
  METHODS
  Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Moreover, many new ADCs are currently under clinical evaluation, as for example the anti-CD79A polatuzumab vedotin in DLBCL. Expert commentary: In few years BV changed the therapeutic scenario of relapsed or refractory HL and ALCL and is rapidly moving toward first-line approval in combination with standard chemotherapy if ongoing randomized trials will demonstrate improved results. Combination strategies with bendamustine in first-salvage HL and with R-CHP in first-line DLBCL appear very promising.
authors.affiliation: a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Merli
authors.affiliation: a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ferrario
authors.affiliation: a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
authors.forename: Margherita
authors.initials: M
authors.lastname: Maffioli
authors.affiliation: a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Olivares
authors.affiliation: a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Stasia
authors.affiliation: b Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo & Department of Molecular Medicine , University of Pavia , Pavia , Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Arcaini
authors.affiliation: a Division of Hematology , University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria , Varese , Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Passamonti
mesh_terms: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D060830:Consolidation Chemotherapy; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D008223:Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D012008:Recurrence; D016879:Salvage Therapy; D059470:Tetraspanins / Q000037:antagonists & inhibitors; D014182:Transplantation, Autologous
chemical_list: D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; C059071:CD37 protein, human; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D059470:Tetraspanins; D000079963:Brentuximab Vedotin
keywords: Antibody-drug conjugates; CD30; Hodgkin lymphoma; brentuximab vedotin; cutaneous T-cell lymphoma; diffuse large B-cell lymphoma; non-peripheral T-cell lymphoma; polatuzumab vedotin